Figure 1

cPLA2α were overexpressed in breast cancer tissues and invasive breast cancer cell lines. (a) A – Immunohistochemistry of cPLA2α in mammary gland flocculus hyperplasia tissues; B – immunohistochemistry of cPLA2α in breast cancer tissues with different histological grades; c – immunohistochemistry of cPLA2α in primary breast cancer tissues and distant metastasis tumor tissues. (b) Kaplan–Meier overall survival analysis of 126 patients with high or low cPLA2α expression. (c) Kaplan–Meier disease-free survival analysis of 126 patients with high or low cPLA2α expression. (d) Western blot of cPLA2α and p-cPLA2α in four pairs of fresh-frozen tissues containing immunohistochemical cancerous tissues and non-cancerous tissues and one pair of primary cancerous tissues and metastasis tissues from breast cancer patient (C: cancer; N: non-cancer; P: primary; M: metastases). Subtypes of different breast cancer patients: Patient 1 (HER2-enriched), Patient 2 (triple negative), Patient 3 (triple negative), Patient 4 (luminal A) and Patient 5 (luminal A). (e) The protein level of cPLA2α and p-cPLA2α in different breast cancer cell lines and normal mammary epithelial cell line MCF-10A. Subtypes of different breast cancer cell lines: MCF-7 (luminal A); T47D (luminal A); Bcap-37 (luminal A); SK-BR-3 (HER2-enriched); MDA-MB-231 (triple negative); ZR-75-30 (triple negative)). Scale bar, 1.0 mm